A Phase 3 trial of Gattex (generic name teduglutide, a Glucagon-like peptide 2 (GLP-2) analogue) has shown promise in reducing the need for intravenous feeding in short bowel syndrome. Nycomed, which has rights to Gattex outside of North America, is expected to file for EU approval this year.

Full article